Understanding how genetic and signaling factors affect cancer treatment response
Linking Genetic, Epigenetic and Signaling Mechanisms of Oncogene Addiction
This study is looking at how certain genes and signals affect melanoma tumors with BRAFV600 mutations and why some of these tumors don’t respond well to treatments; it aims to find better ways to help these tumors by testing new drugs alongside current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-11088817 on NIH RePORTER |
What this research studies
This research investigates the complex interactions between genetic, epigenetic, and signaling mechanisms that influence how tumor cells, particularly those with BRAFV600 mutations like melanoma, respond to targeted therapies. By examining these factors at both the network and single-cell levels, the study aims to identify why some tumors are resistant to treatment and how their dependency on certain signaling pathways can change. The researchers will use a systems pharmacology approach, testing various small-molecule epigenetic modulators alongside existing therapies to enhance treatment effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with BRAFV600 mutated melanoma or other related cancers who are seeking new treatment options.
Not a fit: Patients without BRAFV600 mutations or those with cancers not related to the MAPK pathway may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with BRAFV600 mutated cancers, improving their chances of a durable response to therapy.
How similar studies have performed: Previous research has shown promise in understanding the role of genetic and epigenetic factors in cancer treatment responses, suggesting that this approach could yield valuable insights.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Fallahi-Sichani, Mohammad — University of Virginia
- Study coordinator: Fallahi-Sichani, Mohammad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.